A programozott sejthalál fehérje 1 (PD-1) − programozott sejthalál ligandum 1 (PD-L1) gátlás prediktív diagnosztikája

Translated title of the contribution: Predictive diagnostics of the programmed cell death receptor 1 (PD-1) - programmed cell death ligand 1 (PD-L1) inhibitory therapies

G. Lotz, Gábor Smuk, Éva Kocsmár, Ildikó Kocsmár, J. Tímár

Research output: Contribution to journalArticle

Abstract

In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro diagnostic test with its own evaluation protocol. These tests have different diagnostic sensitivity for PD-L1 protein and the evaluation protocols differ in many respects, as cancer and immune cell positivities are considered variously in the immunotherapy-specific evaluation schemes. Accordingly, in the routine PD-L1 diagnostics, it is crucial to follow the individual therapy-specific technical and evaluation protocols since these are not interchangeable and non-adherence may affect therapeutic efficacy.

Original languageHungarian
Pages (from-to)183-191
Number of pages9
JournalMagyar onkologia
Volume63
Issue number3
Publication statusPublished - Sep 18 2019

Fingerprint

CD274 Antigen
Programmed Cell Death 1 Receptor
Ligands
Immunotherapy
Cell Death
Medical Oncology
Therapeutics
Routine Diagnostic Tests
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A programozott sejthalál fehérje 1 (PD-1) − programozott sejthalál ligandum 1 (PD-L1) gátlás prediktív diagnosztikája. / Lotz, G.; Smuk, Gábor; Kocsmár, Éva; Kocsmár, Ildikó; Tímár, J.

In: Magyar onkologia, Vol. 63, No. 3, 18.09.2019, p. 183-191.

Research output: Contribution to journalArticle

@article{242af0b5eb8a4a59a0e03468a65944ff,
title = "A programozott sejthal{\'a}l feh{\'e}rje 1 (PD-1) − programozott sejthal{\'a}l ligandum 1 (PD-L1) g{\'a}tl{\'a}s predikt{\'i}v diagnosztik{\'a}ja",
abstract = "In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro diagnostic test with its own evaluation protocol. These tests have different diagnostic sensitivity for PD-L1 protein and the evaluation protocols differ in many respects, as cancer and immune cell positivities are considered variously in the immunotherapy-specific evaluation schemes. Accordingly, in the routine PD-L1 diagnostics, it is crucial to follow the individual therapy-specific technical and evaluation protocols since these are not interchangeable and non-adherence may affect therapeutic efficacy.",
author = "G. Lotz and G{\'a}bor Smuk and {\'E}va Kocsm{\'a}r and Ildik{\'o} Kocsm{\'a}r and J. T{\'i}m{\'a}r",
year = "2019",
month = "9",
day = "18",
language = "Hungarian",
volume = "63",
pages = "183--191",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - A programozott sejthalál fehérje 1 (PD-1) − programozott sejthalál ligandum 1 (PD-L1) gátlás prediktív diagnosztikája

AU - Lotz, G.

AU - Smuk, Gábor

AU - Kocsmár, Éva

AU - Kocsmár, Ildikó

AU - Tímár, J.

PY - 2019/9/18

Y1 - 2019/9/18

N2 - In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro diagnostic test with its own evaluation protocol. These tests have different diagnostic sensitivity for PD-L1 protein and the evaluation protocols differ in many respects, as cancer and immune cell positivities are considered variously in the immunotherapy-specific evaluation schemes. Accordingly, in the routine PD-L1 diagnostics, it is crucial to follow the individual therapy-specific technical and evaluation protocols since these are not interchangeable and non-adherence may affect therapeutic efficacy.

AB - In the past years, immunotherapy emerged as a novel modality of clinical oncology. The development and introduction of immune checkpoint inhibitors required the development of companion diagnostics, the PD-L1 protein immunohistochemical tests. Unfortunately, almost all checkpoint inhibitors were exclusively validated by a specific PD-L1 in vitro diagnostic test with its own evaluation protocol. These tests have different diagnostic sensitivity for PD-L1 protein and the evaluation protocols differ in many respects, as cancer and immune cell positivities are considered variously in the immunotherapy-specific evaluation schemes. Accordingly, in the routine PD-L1 diagnostics, it is crucial to follow the individual therapy-specific technical and evaluation protocols since these are not interchangeable and non-adherence may affect therapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85072398248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072398248&partnerID=8YFLogxK

M3 - Article

C2 - 31533137

AN - SCOPUS:85072398248

VL - 63

SP - 183

EP - 191

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -